Antibody Persistence in Australian Adolescents Following Meningococcal C Conjugate Vaccination
Kirsten P Perrett, Peter C Richmond, Ray Borrow, Terry Nolan, Jodie McVernon
PEDIATRIC INFECTIOUS DISEASE JOURNAL | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
This study was funded by Novartis. Drs Perrett and McVernon are recipients of Research Fellowships from the Australian National Health and Medical Research Council.Dr Perrett has received travel support from Novartis for conference attendance and presentation of data at international meetings and honoraria from Pfizer for educational lectures. Dr Richmond has received institutional funding for investigator-initiated research from GlaxoSmithKline Biologicals and Merck and received travel support from Pfizer and Baxter to present study data at international meetings. Dr Borrow has performed contract research on behalf of Public Health England for Baxter, GSK, Merck, Novartis, Pfizer, Sanofi Pasteur and Sanofi Pasteur MSD. Drs Perrett, Nolan and McVernon's institution (MCRI) has received research grants from GSK, Novartis, CSL, Pfizer and Sanofi Pasteur. Dr Nolan has received past payment for a role (now completed) as a member of the independent data and safety monitoring board for GSK's HPV vaccine. Dr McVernon has been an investigator on vaccine and epidemiological studies sponsored by a range of vaccine manufacturers, and in this role has received support for conference attendance, presentation of data and membership of vaccine advisory boards.